Skip to main content

Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease

    Basic Details

    This poster outlines an active comparator, new user cohort study of chronic maintenance azithromycin (>=14 days supplied per dispensing) vs. roflumilast in individuals with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of maintenance use of inhaled corticosteroids (ICS) + long-acting beta-agonists (LABA) + long-acting muscarinic agents (LAMA) in the Sentinel System using administrative claims data from the Centers for Medicare and Medicaid Services (CMS). It was presented at the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. 


    Sruthi Adimadhyam, Laura Hou, Inna Dashevsky, Rongmei Zhang, Yan Li, Marie Bradley, Efe Eworuke, Andrew Clerman, Stacy Chin, Yunzhao Ren, Sally Seymour, Kenneth Quinto, Judith C. Maro, Robert Busch